IMVT

Immunovant, Inc.
CAPPED RATING

Immunovant, Inc., a clinical-stage biopharmaceutical company, develops monoclonal antibodies for the treatment of autoimmune diseases. It develops batoclimab, a novel fully human monoclonal antibody that selectively binds to and inhibits the neonatal fragment crystallizable receptor, which is in Phase IIa clinical trials for the treatment of myasthenia gravis and thyroid eye disease, as well as completed initiation of Phase II clinical trials for the treatment of warm autoimmune hemolytic anemia. The company was incorporated in 2018 is headquartered in New York, New York. Immunovant, Inc. is a subsidiary of Roivant Sciences Ltd.

Immunovant, Inc. (IMVT) is rated C (2.3/5) on Deltasharpe Prism, scored against Healthcare sector peers. Its strongest pillar is Revisions (C+); its weakest is Growth (D+). The rating has held at C for 7 weeks.

Quantitative Factor Evaluation • Updated

Overall Rating
2.3 / 5.0
C
Value
C+
Factor Score 2.5 / 5.0
Growth
D+
Factor Score 1.7 / 5.0
Profitability
C-
Factor Score 2.1 / 5.0
Momentum
C+
Factor Score 2.6 / 5.0
Revisions
C+
Factor Score 2.6 / 5.0

Prism grades are automated quantitative screens, not buy, sell or hold recommendations, and not investment advice. Data may be delayed or contain errors. Terms

Ratings of B- and above are for members.

Register free to see every rating — your first 2 weeks of Premium are on us.

Register — 2 weeks free

Underlying Financial Metrics

P/E Ratio -14.2
EV / EBITDA -12.9
Rev Growth YoY N/A
Gross Margin 0.0%
Price Return 3M -11.4%
Price Return 12M 58.5%
Catalyst Signal 0.00
Market Cap $7.7B
TTM Revenue N/A
Price / Sales N/A
ROE -86.5%

Historical Factor Score Progression

Held C for 7 weeks
Date Value Growth Profitability Momentum Revisions Overall
2026-11-12 C+ (2.5) D+ (1.7) C- (2.1) C+ (2.6) C+ (2.6) C (2.3)
2026-11-05 C+ (2.5) D+ (1.8) C (2.2) C+ (2.7) C+ (2.7) C (2.4)
2026-10-29 C+ (2.5) D+ (1.8) C (2.3) B- (2.9) C+ (2.7) C (2.4)
2026-10-22 C+ (2.5) D+ (1.8) C (2.2) B- (2.9) C+ (2.6) C (2.4)
2026-10-15 C+ (2.5) D+ (1.8) C (2.2) B- (3.0) C+ (2.6) C (2.4)
Page 1 of 4